133 related articles for article (PubMed ID: 36626929)
1. Effect of hormone replacement therapy on intervertebral disc height.
Stevenson TEJ; Brincat MP; Pollacco J; Stevenson JC
Climacteric; 2023 Apr; 26(2):110-113. PubMed ID: 36626929
[TBL] [Abstract][Full Text] [Related]
2. Intervertebral disc height correlates with vertebral body T-scores in premenopausal and postmenopausal women.
Baron YM; Brincat MP; Calleja-Agius J; Calleja N
Menopause Int; 2009 Jun; 15(2):58-62. PubMed ID: 19465670
[TBL] [Abstract][Full Text] [Related]
3. Low intervertebral disc height in postmenopausal women with osteoporotic vertebral fractures compared to hormone-treated and untreated postmenopausal women and premenopausal women without fractures.
Muscat Baron Y; Brincat MP; Galea R; Calleja N
Climacteric; 2007 Aug; 10(4):314-9. PubMed ID: 17653958
[TBL] [Abstract][Full Text] [Related]
4. Intervertebral disc height in treated and untreated overweight post-menopausal women.
Baron YM; Brincat MP; Galea R; Calleja N
Hum Reprod; 2005 Dec; 20(12):3566-70. PubMed ID: 16113041
[TBL] [Abstract][Full Text] [Related]
5. HRT and Vit D in prevention of non-vertebral fractures in postmenopausal women; a 5 year randomized trial.
Komulainen MH; Kröger H; Tuppurainen MT; Heikkinen AM; Alhava E; Honkanen R; Saarikoski S
Maturitas; 1998 Nov; 31(1):45-54. PubMed ID: 10091204
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial comparing hormone replacement therapy (HRT) and HRT plus calcitriol in the treatment of postmenopausal osteoporosis with vertebral fractures: benefit of the combination on total body and hip density.
Gutteridge DH; Holzherr ML; Retallack RW; Price RI; Will RK; Dhaliwal SS; Faulkner DL; Stewart GO; Stuckey BG; Prince RL; Criddle RA; Drury PJ; Tran L; Bhagat CI; Kent GN; Jamrozik K
Calcif Tissue Int; 2003 Jul; 73(1):33-43. PubMed ID: 14506952
[TBL] [Abstract][Full Text] [Related]
7. Identification of early postmenopausal women with no bone response to HRT: results of a five-year clinical trial.
Komulainen M; Kröger H; Tuppurainen MT; Heikkinen AM; Honkanen R; Saarikoski S
Osteoporos Int; 2000; 11(3):211-8. PubMed ID: 10824236
[TBL] [Abstract][Full Text] [Related]
8. The benefit of hormone replacement therapy on bone mass is greater at the vertebral body than posterior processes or proximal femur.
Duan Y; Tabensky A; DeLuca V; Seeman E
Bone; 1997 Nov; 21(5):447-51. PubMed ID: 9356739
[TBL] [Abstract][Full Text] [Related]
9. Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17beta-estradiol and dydrogesterone.
Lippuner K; Haenggi W; Birkhaeuser MH; Casez JP; Jaeger P
J Bone Miner Res; 1997 May; 12(5):806-12. PubMed ID: 9144347
[TBL] [Abstract][Full Text] [Related]
10. [Hormone replacement and selective estrogen receptor modulators (SERMS) in the prevention and treatment of postmenopausal osteoporosis].
Pfeilschifter J
Orthopade; 2001 Jul; 30(7):462-72. PubMed ID: 11515185
[TBL] [Abstract][Full Text] [Related]
11. The prevention of osteoporosis using sequential low-dose hormone replacement therapy with estradiol-17 beta and dydrogesterone.
Lees B; Stevenson JC
Osteoporos Int; 2001; 12(4):251-8. PubMed ID: 11420773
[TBL] [Abstract][Full Text] [Related]
12. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis.
Wimalawansa SJ
Am J Med; 1998 Mar; 104(3):219-26. PubMed ID: 9552083
[TBL] [Abstract][Full Text] [Related]
13. Prospective 10-year study of the determinants of bone density and bone loss in normal postmenopausal women, including the effect of hormone replacement therapy.
Wu F; Ames R; Clearwater J; Evans MC; Gamble G; Reid IR
Clin Endocrinol (Oxf); 2002 Jun; 56(6):703-11. PubMed ID: 12072039
[TBL] [Abstract][Full Text] [Related]
14. Postmenopausal osteoporosis and hormone replacement therapy.
Gambacciani M; Vacca F
Minerva Med; 2004 Dec; 95(6):507-20. PubMed ID: 15785435
[TBL] [Abstract][Full Text] [Related]
15. The protective effect of hormone-replacement therapy on fracture risk is modulated by estrogen receptor alpha genotype in early postmenopausal women.
Salmén T; Heikkinen AM; Mahonen A; Kröger H; Komulainen M; Saarikoski S; Honkanen R; Mäenpää PH
J Bone Miner Res; 2000 Dec; 15(12):2479-86. PubMed ID: 11127213
[TBL] [Abstract][Full Text] [Related]
16. Estrogens and the intervertebral disc.
Calleja-Agius J; Muscat-Baron Y; Brincat MP
Menopause Int; 2009 Sep; 15(3):127-30. PubMed ID: 19723683
[TBL] [Abstract][Full Text] [Related]
17. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis.
Lindsay R; Nieves J; Formica C; Henneman E; Woelfert L; Shen V; Dempster D; Cosman F
Lancet; 1997 Aug; 350(9077):550-5. PubMed ID: 9284777
[TBL] [Abstract][Full Text] [Related]
18. Sublingual administration of micronized estradiol and progesterone, with and without micronized testosterone: effect on biochemical markers of bone metabolism and bone mineral density.
Miller BE; De Souza MJ; Slade K; Luciano AA
Menopause; 2000; 7(5):318-26. PubMed ID: 10993031
[TBL] [Abstract][Full Text] [Related]
19. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
Liberman UA; Weiss SR; Bröll J; Minne HW; Quan H; Bell NH; Rodriguez-Portales J; Downs RW; Dequeker J; Favus M
N Engl J Med; 1995 Nov; 333(22):1437-43. PubMed ID: 7477143
[TBL] [Abstract][Full Text] [Related]
20. Withdrawal of hormone replacement therapy is associated with significant vertebral bone loss in postmenopausal women.
Trémollieres FA; Pouilles JM; Ribot C
Osteoporos Int; 2001; 12(5):385-90. PubMed ID: 11444087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
